These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 31065370)

  • 1. Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
    Nguyen-Tat M; Jäger J; Rey JW; Nagel M; Labenz C; Wörns MA; Galle PR; Marquardt JU
    United European Gastroenterol J; 2019 May; 7(4):529-537. PubMed ID: 31065370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    Wong F; Pappas SC; Curry MP; Reddy KR; Rubin RA; Porayko MK; Gonzalez SA; Mumtaz K; Lim N; Simonetto DA; Sharma P; Sanyal AJ; Mayo MJ; Frederick RT; Escalante S; Jamil K;
    N Engl J Med; 2021 Mar; 384(9):818-828. PubMed ID: 33657294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to Terlipressin and Albumin Is Associated With Improved Liver Transplant Outcomes in Patients With Hepatorenal Syndrome.
    Piano S; Gambino C; Vettore E; Calvino V; Tonon M; Boccagni P; Gringeri E; Germani G; Burra P; Cillo U; Angeli P
    Hepatology; 2021 May; 73(5):1909-1919. PubMed ID: 32870499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
    Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
    Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of hepatorenal syndrome in cirrhotic patients with terlipressin plus albumin. First experience in Mexico.
    Muñoz LE; Alcalá EG; Cordero P; Martínez MA; Vázquez NY; Galindo S; Mendoza E; Segura JJ
    Ann Hepatol; 2009; 8(3):207-11. PubMed ID: 19841499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
    Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
    Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study on clinical outcomes of combination of terlipressin and albumin in Hepatorenal Syndrome.
    Krishna R; Raj J; Dev D; Prasad SC; Reghu R; V SO
    Scand J Gastroenterol; 2020 Jul; 55(7):860-864. PubMed ID: 32634332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment-Related Cost Analysis of Terlipressin for Adults with Hepatorenal Syndrome with Rapid Reduction in Kidney Function.
    Huang X; Bindra J; Chopra I; Niewoehner J; Wan GJ
    Adv Ther; 2023 Dec; 40(12):5432-5446. PubMed ID: 37812332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction in acute kidney injury stage predicts survival in patients with type-1 hepatorenal syndrome.
    Wong F; Boyer TD; Sanyal AJ; Pappas SC; Escalante S; Jamil K
    Nephrol Dial Transplant; 2020 Sep; 35(9):1554-1561. PubMed ID: 30887050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Terlipressin and albumin combination treatment in hepatorenal syndrome.
    Danalioglu A; Cakaloglu Y; Karaca C; Aksoy N; Akyuz F; Ozdil S; Demir K; Besisik F; Boztas G; Mungan Z; Kaymakoglu S; Okten A
    Hepatogastroenterology; 2003 Dec; 50 Suppl 2():ccciii-cccv. PubMed ID: 15244209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
    Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
    Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin: a retrospective analysis.
    Colle I; Durand F; Pessione F; Rassiat E; Bernuau J; Barrière E; Lebrec D; Valla DC; Moreau R
    J Gastroenterol Hepatol; 2002 Aug; 17(8):882-8. PubMed ID: 12164964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the OT-0401 and REVERSE randomised clinical studies.
    Sanyal AJ; Boyer TD; Frederick RT; Wong F; Rossaro L; Araya V; Vargas HE; Reddy KR; Pappas SC; Teuber P; Escalante S; Jamil K
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1390-1402. PubMed ID: 28370090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
    Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
    Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of terlipressin for hepatorenal syndrome: the United States hospital perspective.
    Carter JA; Huang X; Jamil K; Corman S; Ektare V; Niewoehner J
    J Med Econ; 2023; 26(1):1342-1348. PubMed ID: 37729445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective validation of the EASL management algorithm for acute kidney injury in cirrhosis.
    Ma AT; Solé C; Juanola A; Escudé L; Napoleone L; Avitabile E; Pérez-Guasch M; Carol M; Pompili E; Gratacós-Ginés J; Soria A; Rubio AB; Cervera M; Moreta MJ; Morales-Ruiz M; Solà E; Poch E; Fabrellas N; Graupera I; Pose E; Ginès P
    J Hepatol; 2024 Sep; 81(3):441-450. PubMed ID: 38479614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002-2018: A Systematic Review and Meta-Analysis.
    Thomson MJ; Taylor A; Sharma P; Lok AS; Tapper EB
    Dig Dis Sci; 2020 May; 65(5):1539-1548. PubMed ID: 31571102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival.
    Solé C; Solà E; Huelin P; Carol M; Moreira R; Cereijo U; Mas JM; Graupera I; Pose E; Napoleone L; dePrada G; Juanola A; Fabrellas N; Torres F; Morales-Ruiz M; Farrés J; Jiménez W; Ginès P
    Liver Int; 2019 Jul; 39(7):1246-1255. PubMed ID: 30597709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High age and low sodium urine concentration are associated with poor survival in patients with hepatorenal syndrome.
    Hinz M; Wree A; Jochum C; Bechmann LP; Saner F; Gerbes AL; Gerken G; Canbay A
    Ann Hepatol; 2013; 12(1):92-9. PubMed ID: 23293199
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of treatment with terlipressin plus albumin in hepatorenal syndrome diagnosed with the new acute kidney injury versus the conventional criteria.
    Kalambokis GN; Christaki M; Tsiakas I; Despotis G; Milionis HJ
    Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1292-1294. PubMed ID: 31498285
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.